Edmond de Rothschild Holding’s Protalix BioTherapeutics PLX Stock Holding History

Edmond de Rothschild Holding’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-367	Closed	-$2K	–	873
2016 Q3	$2K	Hold	367	–	–	﹤0.01%	833
2016 Q2	$2K	Hold	367	–	–	﹤0.01%	802
2016 Q1	$3K	Hold	367	–	–	﹤0.01%	799
2015 Q4	$4K	Hold	367	–	–	﹤0.01%	795
2015 Q3	$5K	Sell	367 -350	-49%	-$5.56K	﹤0.01%	795
2015 Q2	$14K	Buy	+717	New	+$14.9K	﹤0.01%	752

Other funds holding PLX

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AGC

Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Edmond de Rothschild Holding's PLX Position: Q4 2016 in Review

Edmond de Rothschild Holding sold out of Protalix BioTherapeutics (PLX) in Q4 2016, closing a stake of 367 shares — an estimated $2K sold.

Edmond de Rothschild Holding first reported a position in PLX in Q2 2015 and held it in 6 quarters. The position peaked at $14K in Q2 2015. 33 funds tracked by Wall St. Rank hold PLX as of Q4 2016.

Edmond de Rothschild Holding reported no remaining Protalix BioTherapeutics position as of Q4 2016 after selling out during the quarter.
Edmond de Rothschild Holding sold 367 Protalix BioTherapeutics shares in Q4 2016, an estimated $2K.
Edmond de Rothschild Holding first reported a position in Protalix BioTherapeutics in Q2 2015 and held it in 6 quarters.
Edmond de Rothschild Holding's Protalix BioTherapeutics position peaked at $14K in Q2 2015.
33 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2016.

Based on Edmond de Rothschild Holding's 13F filing for Q4 2016, filed 14 Feb 2017.